The Effect of Monitoring PVP on Clinical Outcomes in Patients With PH

Study Overview
=================
Brief Summary
-----------------
The complications associated with portal hypertension in cirrhosis are the main cause of death in patients with cirrhosis. The level of portal venous pressure is closely related to the prognosis of patients. HVPG (hepatic venous pressure gradient) is the gold standard for predicting portal venous pressure and an important indicator for evaluating the efficacy of NSBBS. However, monitoring HVPG has many limitations，and the clinical application is also limited to a certain extent. Therefore, this study intends to clarify the guiding value of monitoring portal venous pressure in the clinical diagnosis and treatment of portal hypertension patients through a single-center, prospective and observational study. Therefore, this study intends to clarify the guiding value of monitoring portal venous pressure in the clinical diagnosis and treatment of portal hypertension patients through a single-center, prospective and observational study. At the same time, to explore the correlation between HVPG and PPG in cirrhosis patients at different stages and different etiologies, and to evaluate the role of spleen stiffness in predicting the severity of esophageal and gastric varices in patients with portal hypertension, and to find biomarkers to predict the risk of complications related to portal hypertension.

Official Title
-----------------
The Effect of Monitoring Portal Venous Pressure on Clinical Outcomes in Patients With Portal Hypertension: a Prospective, Single-center, Observational Study

Conditions
-----------------
Portal Hypertension

Intervention / Treatment
-----------------
* Other: monitoring portal pressure gradient or hepatic venous pressure gradient


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: With chronic liver disease Age 18-80 years Patients who require a portal pressure measurement at the discretion of the treating physician Voluntarily signed informed consent Exclusion Criteria: With serious cardiopulmonary disease or other diseases affect survival With severe renal dysfunction Concomitant portal vein cavernous degeneration or extensive portal vein thrombosis Women who are planning to become pregnant or who are pregnant or breastfeeding The researcher judged that it was not suitable to participate in this study

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: monitoring portal pressure gradient or hepatic venous pressure gradient|measuring portal pressure gradient or hepatic venous pressure gradient regularly|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Gastroesophageal varices bleeding | Patients with gastroesophageal varices has hematemesis or melena, and active bleeding or red sign can be seen under endoscopy | three years | 
| Ascites | Peritoneal effusion was seen under ultrasound | three years | 
| Hepatic encephalopathy | Patients with altered consciousness or unresponsiveness, accompanied by elevated blood ammonia | three years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death or final follow-up time (3 years) |  | three years |